Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 9/20 | 0.52 |
| ▸ | BACE1 | P56817 | 9/20 | 0.43 |
| ▸ | CTSD | P07339 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354024 | 1.00 | ENPEP (0.52) | ENPEPBACE1CTSD | |
| SCHEMBL30240003 | 0.95 | ENPEP (0.56) | ENPEP | |
| SCHEMBL30563287 | 0.92 | ENPEP (0.43) | ENPEPBACE1CTSD | |
| SCHEMBL30974202 | 0.90 | BACE1 (0.46) | ENPEPBACE1CTSD | |
| SCHEMBL31191678 | 0.88 | ENPEP (0.45) | ENPEPBACE1CTSD | |
| SCHEMBL31013227 | 0.88 | ENPEP (0.53) | ENPEPBACE1 | |
| SCHEMBL31013213 | 0.88 | ENPEP (0.53) | ENPEPBACE1 | |
| SCHEMBL7822201 | 0.87 | ENPEP (0.53) | ENPEP | |
| SCHEMBL12496193 | 0.87 | ENPEP (0.53) | ENPEP | |
| SCHEMBL12496189 | 0.87 | ENPEP (0.53) | ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281557-A1 | METHODS FOR CASCADE AMPLIFICATIONS OF THERAPEUTIC PAYLOADS (CATP) & COMPOSITIONS FOR CANCER IMMUNOTHERAPIES AND GENE THERAPY | SunVax mRNA Therapeutics Inc. (US) | 2025-09-11 | — | — | US | claimed |
| EP-4237493-A1 | POLYMERIC DISINFECTANTS AND USES THEREOF | Technion Research & Development Foundation Ltd. (IL) | 2023-09-06 | — | — | EP | claimed |
| WO-2022091091-A1 | POLYMERIC DISINFECTANTS AND USES THEREOF | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2022-05-05 | — | — | WO | claimed |
| EP-4739326-A2 | PRODUCTION & SECRETION OF AUXIN-LIKE MOLECULES IN BACTERIA | SNIPR Biome ApS (DK) | 2026-05-13 | — | — | EP | disclosed |
| US-12497635-B2 | Means and methods for producing isobutene from acetyl-CoA | GLOBAL BIOENERGIES (FR) | 2025-12-16 | — | — | US | disclosed |
| US-20250369024-A1 | Acyloin Condensation Reactions, Enzymes, and Products Thereof | MOJIA BIOTECH PTE LTD (SG) | 2025-12-04 | — | — | US | disclosed |
| EP-4649157-A2 | ACYLOIN CONDENSATION REACTIONS, ENZYMES, AND PRODUCTS THEREOF | Mojia Biotech Pte. Ltd. (SG) | 2025-11-19 | — | — | EP | disclosed |
| CN-120196869-A | Interpretable zero-sample visual EEG decoding method | 重庆邮电大学 | 2025-06-24 | — | — | CN | disclosed |
| CN-119912414-A | Method for efficiently synthesizing Maculalactone A framework based on Suzuki-Miyaura cross coupling reaction | 山东大学 | 2025-05-02 | — | — | CN | disclosed |
| US-12259396-B2 | Methods and compositions for assessing antibody specificities | SERIMMUNE INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250057859-A1 | CANNABICHROMENEQUINONE AND ANALOGUES THEREOF, AND METHOD OF USING COMPOSITIONS THEREOF AS ANTI-INFLAMMATORY AGENTS | JUVA LIFE, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2023114229-A1 | CANNABICHROMENEQUINONE AND ANALOGUES THEREOF, AND METHOD OF USING COMPOSITIONS THEREOF AS ANTI-INFLAMMATORY AGENTS | JUVA LIFE, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-116245573-A | Method, apparatus, electronic device and medium for recommendation | 北京有竹居网络技术有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | US | disclosed |
| WO-2023287814-A2 | CARBOXYLIC ACID PLATFORM FOR FUEL AND CHEMICAL PRODUCTION AT HIGH CARBON AND ENERGY EFFICIENCY | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-01-19 | — | — | WO | disclosed |
| EP-4076648-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20220295233-A1 | SYSTEM AND METHOD FOR WIFI-BASED INDOOR LOCALIZATION VIA UNSUPERVISED DOMAIN ADAPTATION | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-09-15 | — | — | US | disclosed |
| US-11363416-B2 | System and method for WiFi-based indoor localization via unsupervised domain adaptation | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2022-06-14 | — | — | US | disclosed |
| US-20220145336-A1 | MEANS AND METHODS FOR PRODUCING ISOBUTENE FROM ACETYL-COA | GLOBAL BIOENERGIES (FR) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | DDC, CDA, HMBS | ENPEP 269/4885BACE1 3335/4885CTSD 467/4885 |
| US-20250057859-A1 | CANNABICHROMENEQUINONE AND ANALOGUES THEREOF, AND METHOD OF USING COMPOSITIONS THEREOF AS ANTI-INFLAMMATORY AGENTS | IL5, IFNG, ALOX5 | ENPEP 3267/4885BACE1 865/4885CTSD 2150/4885 |
| US-20250281557-A1 | METHODS FOR CASCADE AMPLIFICATIONS OF THERAPEUTIC PAYLOADS (CATP) & COMPOSITIONS FOR CANCER IMMUNOTHERAPIES AND GENE THERAPY | POLI, STING1, CGAS | ENPEP 1352/4885BACE1 3705/4885CTSD 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.